Structural determinants for selective recognition of peptide ligands for endothelin receptor subtypes ETA and ETB

Journal of Peptide Science

Volumn 15, Issue 7, 2009, Pages 479-491

  Lättig, Jens ^a   Oksche, Alexander ^b   Beyermann, Michael ^a   Rosenthal, Walter ^a,b   Krause, Gerd ^a  

^a LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

BQ3020; Endothelin; ETA; ETB; GPCR; Ligand; Receptor

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN 1 [1,15 ALANINE]; ENDOTHELIN 1 [1,3,11,15 ALANINE]; ENDOTHELIN 1 [11-21]; ENDOTHELIN 1 [3,11 ALANINE]; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; N ACETYL 3,3 DIPHENYL DEXTRO ALANYLLEUCYLASPARTYLISOLEUCYLISOLEUCYLTRYPTOPHAN; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; SUCCINYLENDOTHELIN 1 [8-21][11,15 ALANINE]; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE];

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CONTROLLED STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; SEQUENCE ALIGNMENT;

ANIMALS; BINDING SITES; CATTLE; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDES; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67849103946     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1146     Document Type: Article

References (94)

1. Adachi M, Yang YY, Furuichi Y, Miyamoto C. Cloning and characterization of cDNA encoding human A-type endothelin receptor. Biochem. Biophys. Res. Commun. 1991; 180(3): 1265-1272.
2. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J. Biol. Chem. 1993; 268(25): 19126-19133.
3. Nakamuta M, Takayanagi R, Sakai Y, Sakamoto S, Hagiwara H, Mizuno T, Saito Y, Hirose S, Yamamoto M, Nawata H. Cloning and sequence analysis of a cDNA encoding human non-selective type of endothelin receptor. Biochem. Biophys. Res. Commun. 1991; 177(1): 34-39.
4. B-selective ligands. Mol. Pharmacol. 1997; 52(4): 582-589.
5. Wong SK. G protein selectivity is regulated by multiple intracellular regions of GPCRs. Neurosignals. 2003; 12(1): 1-12. Review.
6. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu.Rev.Physiol. 1999;61: 391-415. Review.
7. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol. Rev. 2002; 54(2): 219-226. Review.
8. Nakajima K, Kubo S, Kumagaye S, Nishio H, Tsunemi M, Inui T, Kuroda H, Chino N, Watanabe TX, Kimura T, Sakakibara S. Structure-activity relationship of endothelin: importanceof charged groups. Biochem. Biophys. Res. Commun. 1989; 163(1): 424-429.
9. B. Amino acid sequence requirements for super stable complex formation with its ligand. J. Biol. Chem. 1994; 269(10): 7509-7513.
10. Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, Rosenthal W. Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol. Pharmacol. 2000; 57(6): 1104-1113.
11. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1): 235-242.
12. B receptor-specific agonist. Biochemistry. 1995; 34(6): 2026-2033.
13. Andersen NH, Chen CP, Marschner TM, Krystek SR, Bassolino DA, Jr. Conformational isomerism of endothelin in acidic aqueous media: a quantitative NOESY analysis. Biochemistry. 1992; 31(5): 1280-1295.
14. Takashima H, Mimura N, Ohkubo T, Yoshida T, Tamaoki H, Kobayashi Y. Distributed computing and NMR constraint-based high-resolution structure determination: applied for bioactive Peptide endothelin-1 to determine C-terminal folding. J. Am. Chem. Soc. 2004; 126(14): 4504-4505.
15. Janes Janes RW, Peapus DH, Wallace BA. The crystal structure of human endothelin. Nat. Struct. Biol. 1994; 1(5): 311-319.
16. Takashima H, Tamaoki H, Teno N, Nishi Y, Uchiyama S, Fukui K, Kobayashi Y. Hydrophobic core around tyrosine for human endothelin-1 investigated by photochemically induced dynamic nuclear polarization nuclear magnetic resonance and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Biochemistry. 2004; 43(44): 13932-13936.
17. Sakamoto A, Yanagisawa M, Sawamura T, Enoki T, Ohtani T, Sakurai T, Nakao K, Toyo-oka T, Masaki T. Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists. J. Biol. Chem. 1993; 268(12): 8547-8553.
18. Rovero P, Galoppini C, Laricchia-Robbio L, Mazzoni MR, Revoltella RP. Structure-activity analysis of C-terminal endothelin analogues. J. Cardiovasc. Pharmacol. 1998; 31(Suppl 1): S251-S254.
19. Macchia M, Barontini S, Ceccarelli F, Galoppini C, Giusti L, Hamdan M, Lucacchini A, Martinelli A, Menchini E, Mazzoni MR, Revoltella RP, Romagnoli F, Rovero P. Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model. Farmaco. 1998; 53(8-9): 545-556.
20. van der Walle CF, Barlow DJ. Investigations of structural requirements for endothelin antagonism. Curr. Med. Chem. 1998; 5(4): 321-335. Review.
21. Forget MA, Lebel N, Sirois P, Boulanger Y, Battistini B, Fournier A. Structure-activity studies of the C-terminal segment of structurally reduced analogues of ET-1. J. Cardiovasc. Pharmacol. 1995; 26(Suppl 3): S107-S110.
22. Forget MA, Lebel N, Sirois P, Boulanger Y, Fournier A. Biological and molecular analyses of structurally reduced analogues of endothelin-1. Mol. Pharmacol. 1996; 49(6): 1071-1079.
23. Tam JP, Liu W, Zhang JW, Galantino M, Bertolero F, Cristiani C, Vaghi F, de Castiglione R. Alanine scan of endothelin: importance of aromatic residues. Peptides. 1994; 15(4): 703-708.
24. Nakajima K, Kumagaye S, Nishio H, Kuroda H, Watanabe TX, Kobayashi Y, Tamaoki H, Kimura T, Sakakibara S. Synthesis of endothelin-1 analogues, endothelin-3, and sarafotoxin S6b: structure-activity relationships. J. Cardiovasc. Pharmacol. 1989; 13(Suppl 5): S8-12; discussion S18.
25. Boivin S, Tessier S, Aubin J, Lampron P, Detheux M, Fournier A. Identification of a binding domain of the endothelin-B receptor using a selective IRL-1620-derived photoprobe. Biochemistry. 2004; 43(36): 11516-11525.
26. Köchl R, Alken M, Rutz C, Krause G, Oksche A, Rosenthal W, Schülein R. The signal peptide of the G protein-coupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the endoplasmic reticulum membrane. J. Biol.Chem. 2002; 277(18): 16131-16138.
27. Lee JA, Elliott JD, Sutiphong JA, Friesen WJ, Ohlstein EH, Stadel JM, Gleason JG, Peishoff CE. Tyr-129 is important to the peptide ligand affinity and selectivity of human endothelin type A receptor. Proc. Natl. Acad. Sci. USA. 1994; 91(15): 7164-7168.
28. A receptor binding cavity. Biochemistry. 1996; 35(8): 2548-2556.
29. Krystek SR, Patel PS, Rose PM, Fisher SM, Kienzle BK, Lach DA, Liu EC, Lynch JS, Novotny J, Webb ML, Jr. Mutation of peptide binding site in transmembrane region of a G protein-coupled receptor accounts for endothelin receptor subtype selectivity. J. Biol. Chem. 1994; 269(17): 12383-12386.
30. B receptor subtype-selective ligand binding while abolishing phospholipase C activation in both receptors. FEBS Lett. 1995; 361(2-3): 243-249.
31. Breu V, Hashido K, Broger C, Miyamoto C, Furuichi Y, Hayes A, Kalina B, Löffler BM, Ramuz H, Clozel M. Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors. Eur. J. Biochem. 1995; 231(1): 266-270.
32. Adachi M, Furuichi Y, Miyamoto C. Identification of specific regions of the human endothelin-B receptor required for high affinity binding with endothelin-3. Biochim. Biophys. Acta. 1994; 1223(2): 202-208.
33. Adachi M, Furuichi Y, Miyamoto C. Identification of a ligand-binding site of the human endothelin-A receptor and specific regions required for ligand selectivity. Eur. J. Biochem. 1994; 220(1): 37-43; Erratum in: Eur. J. Biochem. 1994; 221(3): 1133.
34. Vichi P, Whelchel A, Posada J. Transmembrane helix 7 of the endothelin B receptor regulates downstream signaling. J. Biol.Chem. 1999; 274(15): 10331-10338.
35. B receptors. In QSAR and Molecular Modelling: Concepts, Computational Tools and Biological Applications, Prous Science Publishers: Barcelona, Spain, 1995; 519-525.
36. Clozel M, Breu V, Gray GA, Kalina B, Löffler BM, Burri K, Cassal JM, Hirth G, Müller M, Neidhart W, Ramuz H. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 1994; 270(1): 228-235.
37. Gregan B, Jürgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J. Biol. Chem. 2004; 279(26): 27679-27687.
38. Coin I, Beyermann M, Bienert M. Solid phase peptide synthesis: from standard procedure to the synthesis of difficult sequences. Nature Protocols 2007; 2: 3247-3256.
39. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry. 2001; 40(26): 7761-7772. Review.
40. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 2004; 343(5): 1409-1438.
41. Luecke H, Schobert B, Lanyi JK, Spudich EN, Spudich JL. Crystal structure of sensory rhodopsin II at 2.4 angstroms: insights into color tuning and transducer interaction. Science. 2001; 293(5534): 1499-1503.
42. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic molecules. J. Am. Chem. Soc. 1995; 117: 5179-5197.
43. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK - a program to check the stereochemical quality of protein structures. J. Appl. Cryst. 1993; 26: 283-291.
44. Case DA, Pearlman DA, Caldwell JW, Cheatham TE, III Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Gohlke H, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA. AMBER 7, 2002, University of California, San Francisco.
45. ter Laak AM, Kühne R. Bacteriorhodopsin in a periodic boundary water-vacuum-water box as an example towards stable molecular dynamics simulations of G-protein coupled receptors. Receptors Channels. 1999; 6(4): 295-308.
46. Hewage CM, Jiang L, Parkinson JA, Ramage R, Sadler IH. Design of ET(B) receptor agonists: NMR spectroscopic and conformational studies of ET7-21[Leu7, Aib11, Cys(Acm)15]. Protein Eng. 2002; 15(3): 161-167.
47. Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relationships in G-protein coupled receptors. Methods Neurosci. 1995; 25: 366-428.
48. Itoh Y, Yanagisawa M, Ohkubo S, Kimura C, Kosaka T, Inoue A, Ishida N, Mitsui Y, Onda H, Fujino M, Masaki T. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett. 1988; 231(2): 440-444.
49. Hechter O, Calek A, Jr. Principles of hormone action: the problem of molecular linguistics. Acta. Endocrinol. Suppl. (Copenh). 1974; 191: 39-66.
50. B binding domains using ET-derived photoprobes. Biochimie. 2008; 90(6): 918-929.
51. B) receptor is cleaved by a metalloprotease in an agonist-dependent process. J. Biol. Chem. 2002; 277(46): 43933-43941.
52. Bhatnagar S, Rao GS. Molecular modeling of the complex of endothelin-1 (ET-1) with the endothelin type A (ET(A)) receptor and the rational design of a peptide antagonist. J. Biomol. Struct. Dyn. 2000; 17(6): 957-964.
53. Orry AJ, Wallace BA. Modeling and docking the endothelin G-protein-coupled receptor. Biophys. J. 2000; 79(6): 3083-3094.
54. Katahira R, Umemura I, Takai M, Oda K, Okada T, Nosaka AY. Structural studies on endothelin receptor subtype B specific agonist IRL 1620 [suc-[Glu9, Ala11,15]ET-1(8-21)] and its analogs with dipalmitoyl phosphatidylcholine vesicles by NMR spectroscopy. J. Pept. Res. 1998; 51(2): 155-164.
55. Hewage CM, Jiang L, Parkinson JA, Ramage R, Sadler IH. Developmentof ET(B) selective agonists: solution structure of a linear endothelin-1 analogue, ET-1 [Cys(Acm)(1,15), Ala3, Leu7, dAsp8, Aib11]. J. Biomol. Struct. Dyn. 1998; 16(2): 425-435.
56. Hewage CM, Jiang L, Parkinson JA, Ramage R, Sadler IH. Solution conformation of an ET(B) selective agonist, ET-1[Cys(Acm)1,15,Ala3,Leu7,Aib11], in CD3OH/H2O by 1H NMR and molecular modelling. FEBS Lett. 1998; 425(2): 234-238.
57. B receptor selective agonist ET1-21 [Cys(Acm)1,15, Aib3,11, Leu7] by nuclear magnetic resonance spectroscopy and molecular modelling. J. Pept. Res. 1999; 53(3): 223-233.
58. Ergul A, Tackett RL, Puett D. Identification of receptor binding and activation sites in endothelin-1 by use of site-directed mutagenesis. Circ. Res. 1995; 77(6): 1087-1094.
59. Watanabe TX, Itahara Y, Nakajima K, Kumagaye S, Kimura T, Sakakibara S. The biological activity of endothelin-1 analogues in three different assay systems. J. Cardiovasc. Pharmacol. 1991; 17(Suppl 7): S5-S9.
60. Bonini JA, Jones KA, Adham N, Forray C, Artymyshyn R, Durkin MM, Smith KE, Tamm JA, Boteju LW, Lakhlani PP, Raddatz R, Yao WJ, Ogozalek KL, Boyle N, Kouranova EV, Quan Y, Vaysse PJ, Wetzel JM, Branchek TA, Gerald C, Borowsky B. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 2000; 275(50): 39324-39331.
61. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J. Biol. Chem. 1998; 273(28): 17299-17302. Review.
62. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 2004; 103(1): 21-80. Review.
63. Shi L, Javitch JA. A role for information collection, management, and integration in structure-function studies of G-protein coupled receptors. Curr. Pharm. Des. 2006; 12(14): 1771-1783. Review.
64. Stenkamp RE, Teller DC, Palczewski K. Crystal structure of rhodopsin: a G-protein-coupled receptor. Chembiochem. 2002; 3(10): 963-967. Review.
65. Strader CD, Fong TM, Tota MR, Underwood D, Dixon RA. Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 1994; 63: 101-132. Review.
66. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, Ling L. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature. 2004; 429(6988): 188-193.
67. Stitham J, Stojanovic A, Merenick BL, O'Hara KA, Hwa J. The unique ligand-binding pocket for the human prostacyclin receptor. Site-directed mutagenesis and molecular modeling. J. Biol. Chem. 2003; 278(6): 4250-4257.
68. Tunaru S, Lättig J, Kero J, Krause G, Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol. Pharmacol. 2005; 68(5): 1271-1280.
69. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 2004; 279(46): 48024-48037.
70. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, Kobilka B. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 2005; 280(23): 22165-22171.
71. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science. 2007; 318(5854): 1258-1265.
72. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007; 450(7168): 383-387.
73. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science. 2007; 318(5854): 1266-1273.
74. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature. 2008; 454(7203): 486-491.
75. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 Angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322(5905): 1211-1217.
76. Dragic T, Trkola A, Lin SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, Wu L, Mackay CR, Allaway GP, Sakmar TP, Moore JP, Maddon PJ. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 1998; 72(1): 279-285.
77. Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology. 2001; 287(2): 382-390.
78. Kleinau G, Claus M, Jaeschke H, Mueller S, Neumann S, Paschke R, Krause G. Contacts between extracellular loop two and transmembrane helix six determine basal activity of the thyroid-stimulating hormone receptor. J. Biol. Chem. 2007; 282(1): 518-525.
79. Lee JA, Brinkmann JA, Longton ED, Peishoff CE, Lago MA, Leber JD, Cousins RD, Gao A, Stadel JM, Kumar CS, Ohlstein EH, Gleason JG, Elliott JD. Lysine 182 of endothelin B receptor modulates agonist selectivity and antagonist affinity:evidence for the overlap of peptide and non-peptide ligand binding sites. Biochemistry. 1994; 33(48): 14543-14549.
80. Imamura F, Arimoto I, Fujiyoshi Y, Doi T. W276 mutation in the endothelin receptor subtype B impairs Gq coupling but not Gi or Go coupling. Biochemistry. 2000; 39(4): 686-692.
81. Fuchs S, Amiel J, Claudel S, Lyonnet S, Corvol P, Pinet F. Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: evidence for selective loss of Gi coupling. Mol. Med. 2001; 7(2): 115-124.
82. Abe Y, Sakurai T, Yamada T, Nakamura T, Yanagisawa M, Goto K. Functional analysis of five endothelin-B receptor mutations found in human Hirschsprung disease patients. Biochem. Biophys. Res. Commun. 2000; 275(2): 524-531.
83. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332(6163): 411-415.
84. Yanagisawa M, Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol. Sci. 1989; 10(9): 374-378. Review.
85. Aimoto S, Hojoh H, Takasaki C. Studies on the disulfide bridges of sarafotoxins. Chemical synthesis of sarafotoxin S6B and its homologue with different disulfide bridges. Biochem. Int. 1990; 21(6): 1051-1057.
86. Williams DL, Jones KL, Pettibone DJ, Lis EV, Clineschmidt BV, Jr. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem. Biophys. Res. Commun. 1991; 175(2): 556-561.
87. Randall MD, Douglas SA, Hiley CR. Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat. Br. J. Pharmacol. 1989; 98(2): 685-699.
88. Saeki T, Ihara M, Fukuroda T, Yamagiwa M, Yano M. [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity. Biochem. Biophys. Res. Commun. 1991; 179(1): 286-292.
89. Peter MG, Davenport AP. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br. J. Pharmacol. 1996; 117(3): 455-462.
90. B receptor. Biochem. Biophys. Res. Commun. 1992;184(2): 953-959.
91. Doherty AM, Cody WL, DePue PL, He JX, Waite LA, Leonard DM, Leitz NL, Dudley DT, Rapundalo ST, Hingorani GP, Haleen SJ, Ladouceur DM, Hill KE, Flynn MA, Reynolds EE. Structure-activity relationships of C-terminal endothelin hexapeptide antagonists. J. Med. Chem. 1993; 36(18): 2585-2594.
92. Urade Y, Fujitani Y, Oda K, Watakabe T, Umemura I, Takai M, Okada T, Sakata K, Karaki H. An endothelin B receptor-selective antagonist: IRL 1038, [Cys11-Cys15]-endothelin-1(11-21). FEBS Lett. 1992; 311(1): 12-16.
93. Humphrey W, Dalke A, Schulten K. "VMD - Visual Molecular Dynamics". J. Molec. Graphics. 1996; 14: 33-38. vol. pp.
94. Molecular Operating Environment (MOE), Version 2008. 10, Chemical Computing Group, Inc.: Montreal, Quebec, Canada 2008; http://www.chemcomp.com.